Title: 섬망 치료에 있어서 지프라시돈(Ziprasidone)과 리스페리돈(Risperidone)의 효과 비교

Objectives：It has been shown that risperidone, an atypical antipsychotics, has effectiveness for treatment of delirium as good as haloperidol and has less side effects than haloperidol. Ziprasidone also has less extrapyramidal and anticholinergic side effects, but there has been little information published on ziprasidone for the treatment of patients with delirium. Therefore, this study investigated whether ziprasidone had effectiveness for treatment of delirium and whether there was a differential effect between risperidone and ziprasidone. Methods：Sixteen patients with delirium were enrolled in this study. All subjects(16 patients) were randomized to receive either risperidone(7 patients) or ziprasidone(9 patients) with fixed dose at the first day of treatment. Risperidone group was given 1mg and ziprasidone group was given 20mg at the first day of treatment in the night. Then, all subjects received either medications with flexible doses according to judgement on clinical status of patients. The effectiveness was evaluated using Clinical Global Impression-Severity(CGI-S), Korean version of Delirium Rating Scale(K-DRS), Korean Mini Mental Status Examination(K-MMSE), and Korean version of Delirium Rating Scale- Revised-98. The side effects was evaluated using Extrapyramidal Symptom Rating Scale(ESRS) which was administered by a trained psychiatrist. Results：There was no significant difference between both groups in the baseline K-DRS, K-DRS-R-98, KMMSE and CGI scores. At the seventh day of the treatment, K-DRS, K-DRS-R-98 and CGI scores were significantly decreased from the baseline in the ziprasidone treatment group, but not in risperidone treatment group. Conclusion：These results suggest that ziprasidone appears to be more effective than risperidone for treatment of delirium.
Objectives：It has been shown that risperidone, an atypical antipsychotics, has effectiveness for treatment of delirium as good as haloperidol and has less side effects than haloperidol. Ziprasidone also has less extrapyramidal and anticholinergic side effects, but there has been little information published on ziprasidone for the treatment of patients with delirium. Therefore, this study investigated whether ziprasidone had effectiveness for treatment of delirium and whether there was a differential effect between risperidone and ziprasidone. Methods：Sixteen patients with delirium were enrolled in this study. All subjects(16 patients) were randomized to receive either risperidone(7 patients) or ziprasidone(9 patients) with fixed dose at the first day of treatment. Risperidone group was given 1mg and ziprasidone group was given 20mg at the first day of treatment in the night. Then, all subjects received either medications with flexible doses according to judgement on clinical status of patients. The effectiveness was evaluated using Clinical Global Impression-Severity(CGI-S), Korean version of Delirium Rating Scale(K-DRS), Korean Mini Mental Status Examination(K-MMSE), and Korean version of Delirium Rating Scale- Revised-98. The side effects was evaluated using Extrapyramidal Symptom Rating Scale(ESRS) which was administered by a trained psychiatrist. Results：There was no significant difference between both groups in the baseline K-DRS, K-DRS-R-98, KMMSE and CGI scores. At the seventh day of the treatment, K-DRS, K-DRS-R-98 and CGI scores were significantly decreased from the baseline in the ziprasidone treatment group, but not in risperidone treatment group. Conclusion：These results suggest that ziprasidone appears to be more effective than risperidone for treatment of delirium.